Access: Lupus Research -- Lupus Drug Development
Research Summaries from 2012
Rontalizumab: A Potential New Lupus Therapy
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity. The results suggest that rontalizumab is safe for use in people with lupus and effectively reduces levels of interferon-regulated genes, but not interferon-regulated proteins. Rontalizumab is now being tested in Phase II clinical trials, in people with more severe lupus disease activity, in order to further evaluate its effects on lupus.
Research Summaries from 2011
Belimumab Allows For Reduction in Steroid Use for People with Lupus
One way to test whether a new treatment for lupus is effective is to see whether it allows people to reduce the amount of steroids they are taking. In this study, the researchers hoped to learn whether treatment with belimumab could reduce the use of steroids in people with active lupus.
Read more >>
Epratuzumab is Safe and Effective for Treatment of Lupus in Phase II Trials
Epratuzumab is an investigational agent for the treatment of lupus. It is an antibody that binds to a protein called CD22 on B cells, which are white blood cells known to be hyperactive in many people with lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus. They also wanted to find the best way to give the treatment (which dose and how often to give it) to get the best possible effects.